Altomare Ivy, Irwin Blair, Zafar Syed Yousuf, Houck Kevin, Maloney Bailey, Greenup Rachel, Peppercorn Jeffrey
Duke University Medical Center; Duke Cancer Institute, Durham; North Carolina State University, Raleigh, NC; Massachusetts General Hospital; and Harvard Medical School, Boston, MA
Duke University Medical Center; Duke Cancer Institute, Durham; North Carolina State University, Raleigh, NC; Massachusetts General Hospital; and Harvard Medical School, Boston, MA.
J Oncol Pract. 2016 Mar;12(3):e281-8, 247-8. doi: 10.1200/JOP.2015.007401. Epub 2016 Feb 16.
We surveyed US cancer doctors to examine current attitudes toward cost discussions and how they influence decision making and practice management.
We conducted a self-administered, anonymous, electronic survey of randomly selected physician ASCO members to evaluate the frequency and nature of cost discussions reported by physicians, attitudes toward discussions of cost in clinics, and potential barriers.
A total of 333 of 2,290 physicians responded (response rate [RR], 15%; adjusted RR after omitting nonpracticing physician ASCO members, 25%), Respondent practice settings were 45% academic and 55% community/private practice. Overall, 60% reported addressing costs frequently/always in clinic, whereas 40% addressed costs rarely/never. The largest reported barrier was lack of resources to guide discussions. Those who reported frequent discussions were significantly more likely to prioritize treatments in terms of cost and believed doctors should explain patient and societal costs. A total of 36%did not believe that doctors should discuss costs with patients. Academic practitioners were significantly less likely to discuss costs (odds ratio [OR], 0.41; P = .001) and felt less prepared for such discussions (OR, 0.492; P = .005) but were more likely to consider costs to the patient (OR, 2.68; P = .02) and society (OR, 1.822; P = .02).
Although the majority of respondents believe it is important to consider out-of-pocket costs to patients, a substantial proportion do not discuss or consider costs of cancer care. Lack of consensus on the importance of such discussions and uncertainty regarding the optimal timing and content appear to be barriers to addressing costs of care with patients.
我们对美国癌症医生进行了调查,以研究他们目前对成本讨论的态度,以及这些态度如何影响决策和实践管理。
我们对随机挑选的美国临床肿瘤学会(ASCO)会员医生进行了一项自行填写的匿名电子调查,以评估医生报告的成本讨论频率和性质、对临床成本讨论的态度以及潜在障碍。
2290名医生中共有333人回复(回复率[RR]为15%;剔除非执业ASCO会员医生后的调整回复率为25%)。回复者的执业环境为45%是学术机构,55%是社区/私人诊所。总体而言,60%的人报告在临床中经常/总是讨论成本,而40%的人很少/从不讨论成本。报告的最大障碍是缺乏指导讨论的资源。那些报告经常讨论的人在根据成本对治疗进行优先级排序方面的可能性显著更高,并且认为医生应该解释患者和社会成本。共有36%的人不认为医生应该与患者讨论成本。学术从业者讨论成本的可能性显著更低(优势比[OR]为0.41;P = 0.001),并且对这类讨论的准备程度更低(OR为0.492;P = 0.005),但更有可能考虑患者(OR为2.68;P = 0.02)和社会(OR为1.822;P = 0.02)的成本。
尽管大多数受访者认为考虑患者自付成本很重要,但仍有相当一部分人不讨论或不考虑癌症治疗成本。在这类讨论的重要性上缺乏共识,以及在最佳时机和内容方面的不确定性,似乎是与患者讨论护理成本的障碍。